WILLIAM M. BENNETT, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: I am writing to you on our article, "Guidelines for Drug Therapy in Renal Failure" published in the June issue (Ann Intern Med 86:754-783, 1977). In looking over the tables I have discovered that the drug tobramycin was inadvertently omitted under the category of aminoglycoside antibiotics in Table 1. Because this drug is widely used, perhaps the recommendations for this drug should be published in the "Letters" section. The pertinent information follows.
Tobramycin has a major route of excretion (renal). The half-life, under normal circumstances, is 2 h and with end-stage renal disease is extended to 24
BENNETT WM. Addenda to Drug Guidelines. Ann Intern Med. ;87:794. doi: 10.7326/0003-4819-87-6-794_1
Download citation file:
© 2019
Published: Ann Intern Med. 1977;87(6):794.
DOI: 10.7326/0003-4819-87-6-794_1